One of the most common mutations in AML, the FLT3 mutation, occurs in approximately 30% of AML cases and is associated with a poor prognosis.[37] FLT3 inhibitors have emerged as a promising treatment option for AML, effectively targeting and inhibiting the aberrant FLT3 signaling that drives leukemic cell proliferation. The gene discussed is FLT3; the disease is acute myeloid leukemia.